Researchers have identified YAP and TAZ as crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis, ...
Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
An international team of researchers has, for the first time, created a detailed map of the location and identity of individual cells in the adult lung, both from healthy lungs and in lungs from ...
A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback